查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1770880

女性避孕市場－全球產業規模、佔有率、趨勢、機會和預測（按避孕藥物、設備、地區和競爭細分，2020-2030 年）

Female Contraceptive Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Contraceptive Drugs, By Device, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球女性避孕市場價值為 150.1 億美元，預計到 2030 年將以 6.24% 的複合年成長率強勁成長。該市場包括各種各樣的產品和設備，旨在防止意外懷孕並支持女性的生殖自主權。避孕選擇包括避孕藥、植入物和貼片等荷爾蒙方法，以及屏障避孕法、子宮內避孕器 (IUD) 和緊急避孕藥。該行業在計劃生育、降低孕產婦死亡率和支持全球婦女健康方面發揮關鍵作用。人們對生殖健康的認知不斷提高、醫療保健的可及性不斷提高、政府的支持性舉措以及不斷發展的社會規範正在推動需求。根據聯合國人口基金會 2022 年的報告，全球每年發生近 1.21 億例意外懷孕，凸顯了對有效避孕解決方案的迫切需求。產品開發的創新和文化觀念的轉變繼續加強全球市場擴張。

市場概覽
預測期 2026-2030
2024年市場規模 150.1億美元
2030年市場規模 214.1億美元
2025-2030 年複合年成長率 6.24%
成長最快的領域 皮下避孕植入物
最大的市場 北美洲

關鍵市場促進因素

婦女賦權

主要市場挑戰

有限的訪問和意識

主要市場趨勢

副作用較少的荷爾蒙避孕藥

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球女性避孕市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 避孕藥（口服避孕藥、避孕針劑、外用避孕藥、殺精劑）
    • 按裝置分類（女用保險套、隔膜和帽子、陰道環、避孕海綿、皮下避孕植入物、子宮內避孕器 (IUCD)、其他）
    • 按地區
    • 按公司分類（2024）
  • 產品市場圖
    • 避孕藥
    • 按設備
    • 按地區

第6章：北美女性避孕市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲女性避孕市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙

第8章：亞太女性避孕市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國

第9章：南美洲女性避孕市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲女性避孕市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第13章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.,LTD.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 16167

The Global Female Contraceptive Market was valued at USD 15.01 billion in 2024 and is projected to witness strong growth with a CAGR of 6.24% through 2030F. This market includes a diverse range of products and devices designed to prevent unintended pregnancies and support reproductive autonomy for women. Contraceptive options include hormonal methods like pills, implants, and patches, as well as barrier methods, intrauterine devices (IUDs), and emergency contraceptives. The sector plays a key role in family planning, reducing maternal mortality, and supporting women's health globally. Growing awareness about reproductive health, increased healthcare accessibility, supportive government initiatives, and evolving social norms are propelling demand. According to the UNFPA's 2022 report, nearly 121 million unintended pregnancies occur globally each year, highlighting the critical need for effective contraceptive solutions. Innovation in product development and shifting cultural attitudes continue to strengthen market expansion worldwide.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 15.01 Billion
Market Size 2030USD 21.41 Billion
CAGR 2025-20306.24%
Fastest Growing SegmentSub-dermal Contraceptive Implants
Largest MarketNorth America

Key Market Drivers

Women's Empowerment

Women's empowerment is a major catalyst for growth in the female contraceptive market, influencing healthcare decision-making and reproductive autonomy. Educated and informed women are better equipped to make decisions regarding contraception that align with their health needs and personal circumstances. Greater empowerment improves access to healthcare services, prompting more women to utilize family planning clinics and seek out reliable contraceptive options. As economic independence grows, women are increasingly able to afford and prioritize contraceptive products and services. This economic and social empowerment drives demand, encouraging pharmaceutical companies to innovate and expand contraceptive offerings to meet diverse needs across different populations.

Key Market Challenges

Limited Access and Awareness

Limited access to and awareness of contraceptive options remains a major barrier in the global female contraceptive market, particularly in underprivileged and rural areas. Many women face financial, cultural, or geographic constraints that prevent them from obtaining reliable contraceptives. A lack of education and knowledge about available methods also contributes to low adoption rates. Addressing this challenge requires coordinated efforts by governments, NGOs, and international health organizations to expand education campaigns and improve access to family planning services. By empowering women with accurate information and affordable options, these initiatives aim to reduce disparities and foster informed reproductive choices.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

A significant trend shaping the female contraceptive market is the development of hormonal contraceptives designed to minimize side effects. Manufacturers are investing in research to produce solutions that effectively prevent pregnancy while reducing issues such as mood changes, weight gain, and reduced libido. These innovations aim to enhance the user experience, making hormonal contraceptives more appealing and acceptable to a broader population. As awareness of long-term reproductive health grows, demand for safer, user-friendly options is driving the evolution of new-generation hormonal contraceptives with improved tolerability and efficacy.

Key Market Players

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.LTD.

Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Contraceptive Market, By Contraceptive Drugs:

  • Oral Contraceptives
  • Contraceptive Injections
  • Topical Contraceptives
  • Spermicides

Female Contraceptive Market, By Device:

  • Female Condoms
  • Diaphragms and Caps
  • Vaginal Rings
  • Contraceptive Sponges
  • Sub-dermal Contraceptive Implants
  • Intra Uterine Contraceptive Devices (IUCDs)
  • Others

Female Contraceptive Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

Global Female Contraceptive market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Female Contraceptive Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 5.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Contraceptive Drugs
    • 5.3.2. By Device
    • 5.3.3. By Region

6. North America Female Contraceptive Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 6.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Female Contraceptive Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Contraceptive Drugs
        • 6.3.1.2.2. By Device
    • 6.3.2. Canada Female Contraceptive Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Contraceptive Drugs
        • 6.3.2.2.2. By Device
    • 6.3.3. Mexico Female Contraceptive Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Contraceptive Drugs
        • 6.3.3.2.2. By Device

7. Europe Female Contraceptive Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 7.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Female Contraceptive Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Contraceptive Drugs
        • 7.3.1.2.2. By Device
    • 7.3.2. United Kingdom Female Contraceptive Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Contraceptive Drugs
        • 7.3.2.2.2. By Device
    • 7.3.3. France Female Contraceptive Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Contraceptive Drugs
        • 7.3.3.2.2. By Device
    • 7.3.4. Italy Female Contraceptive Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Contraceptive Drugs
        • 7.3.4.2.2. By Device
    • 7.3.5. Spain Female Contraceptive Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Contraceptive Drugs
        • 7.3.5.2.2. By Device

8. Asia-Pacific Female Contraceptive Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 8.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Female Contraceptive Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Contraceptive Drugs
        • 8.3.1.2.2. By Device
    • 8.3.2. Japan Female Contraceptive Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Contraceptive Drugs
        • 8.3.2.2.2. By Device
    • 8.3.3. India Female Contraceptive Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Contraceptive Drugs
        • 8.3.3.2.2. By Device
    • 8.3.4. Australia Female Contraceptive Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Contraceptive Drugs
        • 8.3.4.2.2. By Device
    • 8.3.5. South Korea Female Contraceptive Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Contraceptive Drugs
        • 8.3.5.2.2. By Device

9. South America Female Contraceptive Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 9.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Female Contraceptive Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Contraceptive Drugs
        • 9.3.1.2.2. By Device
    • 9.3.2. Argentina Female Contraceptive Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Contraceptive Drugs
        • 9.3.2.2.2. By Device
    • 9.3.3. Colombia Female Contraceptive Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Contraceptive Drugs
        • 9.3.3.2.2. By Device

10. Middle East and Africa Female Contraceptive Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Female Contraceptive Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Contraceptive Drugs
        • 10.3.1.2.2. By Device
    • 10.3.2. Saudi Arabia Female Contraceptive Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Contraceptive Drugs
        • 10.3.2.2.2. By Device
    • 10.3.3. UAE Female Contraceptive Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Contraceptive Drugs
        • 10.3.3.2.2. By Device

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Bayer AG
    • 14.1.1. Business Overview
    • 14.1.2. Product Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Mayer Laboratories Inc
  • 14.3. Pfizer Inc
  • 14.4. Mylan Pharmaceuticals Inc
  • 14.5. Teva Pharmaceutical Industries Ltd
  • 14.6. Organon & Co.
  • 14.7. Agile Therapeutics Inc
  • 14.8. Lupin Pharmaceuticals Inc
  • 14.9. The Female Health Company
  • 14.10. FUJI LATEX CO.,LTD.

15. Strategic Recommendations

16.About Us & Disclaimer